The obituary has been written on Eli Lilly & Co.'s cholesterol drug evacetrapib and likely for the class of CETP inhibitors as a whole. While the big pharma stopped development of the drug in October, data released at the American College of Cardiology shows the class and the theory behind it might be faulty.
